NaseemaGangatMD

Instructor, Internal Medicine, Mayo Medical School

Dr. Gangat is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2007 - 2010
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2004 - 2007
Aga Khan Medical CollegeClass of 2002

Actuate 1901: 9-ING-41 in Myelofibrosis Start of enrollment: 2020 Aug 20
Completed
Phase 2
Roles: Contact

PubMed

TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance.
Ayalew Tefferi, Maymona Abdelmagid, Giuseppe G Loscocco, Saubia Fathima, Kebede H Begna
American Journal of Hematology. 2025-04-01
Prevalence of cytopenia(s) and somatic variants in patients with DDX41 mutant germline predisposition syndrome.
Yael Kusne, Talha Badar, Terra Lasho, Ludovica Marando, Abhishek A Mangaonkar
British Journal of Haematology. 2025-03-04
1 citations
Outcome of Splenectomy in JAK2 Inhibitor Treated Patients With Myelofibrosis: A Mayo Clinic Experience in 34 Consecutive Cases.
Patricia Carey, Animesh Pardanani, Patrick Starlinger, Ayalew Tefferi, Naseema Gangat
American Journal of Hematology. 2025-03-01

Journal Articles

MPL-Mutated Essential Thrombocythemia: A Morphologic Reappraisal
Naseema Gangat, Natasha Szuber, Rhett P Ketterling, Nature
Determinants of Long-Term Outcome in Type 1 Calreticulin-Mutated Myelofibrosis
Naseema Gangat, Natasha Szuber, Rhett P Ketterling, Nature